K.H. Jung

Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial

Éric Pujade-Lauraine, Keiichi Fujiwara, JA Ledermann et al. · Gynecologic Oncology · 2019 · 64 citations

Medicine, Oncology, Pharmacology +15

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

Patrick Schmid, K.H. Jung, Piotr J. Wysocki et al. · Annals of Oncology · 2022 · 43 citations

Medicine, Oncology, Pharmacology +16

CD24 negativity reprograms mitochondrial metabolism to PPARα and NF-κB-driven fatty acid β-oxidation in triple-negative breast cancer

Divya Murthy, Debasmita Dutta, Kuldeep S. Attri et al. · Cancer Letters · 2024 · 35 citations · Full text

Life Sciences, Cell Biology, Oncology +15

Reproductive Factors and Subtypes of Breast Cancer Defined by Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2: A Register-Based Study From Korea

Jung Sun Lee, Minkyung Oh, S.H. Ahn et al. · Clinical Breast Cancer · 2014 · 11 citations

Medicine, Endocrinology, Oncology +9

Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway

Jun Hyoung Park, K.H. Jung, Dongya Jia et al. · Cell Reports Medicine · 2025 · 11 citations · Full text

Medicine, Oncology, Pharmacology +16